Clinical cure (bacteriological per protocol analysis) · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes clinical cure (bacteriological per protocol analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Relapse · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes relapse (ITT analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Relapse (bacteriological per protocol analysis) · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes relapse (bacteriological per protocol analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Adverse events (ITT analysis) · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes adverse events (ITT analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Clinical cure · group A streptococcal pharyngitis
It is very uncertain whether azithromycin changes clinical cure (ITT analysis) compared with amoxicillin (very low certainty).
1 finding from 1 review
Clinical cure · bacterial boils (furuncles and carbuncles)
It is very uncertain whether azithromycin changes clinical cure (measured 7 days after treatment) compared with cefaclor (very low certainty).
1 finding from 1 review
Severe adverse events leading to withdrawal of treatment · bacterial boils (furuncles and carbuncles)
1 finding from 1 review
Quality of life · bacterial boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Recurrence of folliculitis or boil following completion of treatment · bacterial boils (furuncles and carbuncles)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events not leading to withdrawal of treatment · bacterial boils (furuncles and carbuncles)
It is very uncertain whether azithromycin changes minor adverse events not leading to withdrawal of treatment… compared with cefaclor (very low certainty).
1 finding from 1 review
All‐cause mortality at day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in all‐cause mortality at day 28 compared with placebo or standard of care alone (high certainty).
1 finding from 1 review
Resolution of symptoms · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
Azithromycin showed no clear difference in all initial symptoms resolved (asymptomatic) at day 14 compared with placebo or standard of care alone (low certainty).
1 finding from 1 review
Time to resolution · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Quality of life at longest · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Adverse events during treatment period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Serious adverse events during the study period · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Arrhythmias · all trials contributing results to the summary of findings table included people with mild disease (WHO scale 1 to 3)§
1 finding from 1 review
Clinical worsening: need for invasive mechanical ventilation, or death at up to day 28 · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in worsening of clinical status: participants with clinical… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Clinical improvement: discharged alive ( · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
Azithromycin showed no clear difference in improvement of clinical status: participants discharged alive at day… compared with placebo or standard of care alone (moderate certainty).
1 finding from 1 review
Quality of life at longest · people with moderate to severe disease (WHO scale 4–9); all studies contributing results to the summary of findings table included people…
1 finding from 1 review